Scopus Biopharma

Scopus Biopharma Book Value per Share

The Book Value per Share of Scopus Biopharma (SCPS) as of Nov 19, 2026 is -0.17 USD. In the previous year, Book Value per Share was 0.10 USD — a change of -275.79% (lower).

Book Value per Share

-0.17USD

YoY

-275.79%

Last updated:

Book Value per Share of Scopus Biopharma is 2022 -0.17 USD. Book Value per Share of Scopus Biopharma was 2021 0.10 USD. It decreases by -275.79% lower compared to the previous year.

The Scopus Biopharma Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2017
0.00 USD
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.04 USD
Jan 1, 2021
0.10 USD
Jan 1, 2022
-0.17 USD
The Scopus Biopharma Book Value per Share history
YEARBook Value per ShareYoY
-0.17USD-275.79%
0.10USD-319.39%
-0.04USD+2,110.05%
-0.00USD+1,455.75%
-0.00USD-105.24%
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

Book Value per Share of Scopus Biopharma is -0.17 USD in 2022.

Book Value per Share of Scopus Biopharma changed from 0.10 USD to -0.17 USD, representing a -275.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Scopus Biopharma

All Key Metrics — Scopus Biopharma